Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.
Blyme A, Asferg C, Nielsen OW, Sehestedt T, Kesäniemi YA, Gohlke-Bärwolf C, Boman K, Willenheimer R, Ray S, Nienaber CA, Rossebø A, Wachtell K, Olsen MH. Blyme A, et al. Among authors: boman k. Open Heart. 2015 Feb 4;2(1):e000152. doi: 10.1136/openhrt-2014-000152. eCollection 2015. Open Heart. 2015. PMID: 25685360 Free PMC article.
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K. Nielsen OW, et al. Among authors: boman k. Circulation. 2016 Aug 9;134(6):455-68. doi: 10.1161/CIRCULATIONAHA.115.021213. Epub 2016 Aug 2. Circulation. 2016. PMID: 27486164 Clinical Trial.
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, Papademetriou V, Nieminen MS, Rokkedal J, Dahlöf B, Devereux RB. Olsen MH, et al. Among authors: boman k. Am J Cardiol. 2004 Oct 15;94(8):1076-80. doi: 10.1016/j.amjcard.2004.06.074. Am J Cardiol. 2004. PMID: 15476632 Clinical Trial.
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Rossebø AB, et al. Among authors: boman k. Am J Cardiol. 2007 Apr 1;99(7):970-3. doi: 10.1016/j.amjcard.2006.10.064. Epub 2007 Feb 15. Am J Cardiol. 2007. PMID: 17398194 Clinical Trial.
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Rossebø AB, et al. Among authors: boman k. N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2. N Engl J Med. 2008. PMID: 18765433 Free article. Clinical Trial.
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R. Gerdts E, et al. Among authors: boman k. Am J Cardiol. 2010 Dec 1;106(11):1634-9. doi: 10.1016/j.amjcard.2010.07.042. Epub 2010 Oct 14. Am J Cardiol. 2010. PMID: 21094366 Clinical Trial.
411 results